A Phase 3 interventional study of Tadalafil and Placebo in Muscular Dystrophy, Duchenne, sponsored by Eli Lilly and Company. Terminated at 62 sites in 16 countries. Open to male participants aged 7 Years to 14 Years. Per ClinicalTrials.gov, last updated 2019-10-09.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 233 studies in Muscular Dystrophy, Duchenne with a site in United States — 35 open to participants now, 61 under way, 8 of them phase 3. Muscular Dystrophy, Duchenne · United States.
Among the 233 studies in Muscular Dystrophy, Duchenne with a site in United States, this one is the 3rd largest by enrollment of the 172 interventional ones that give a count, is one of 13 that started in 2013, is one of 32 in phase 3, and was the 60th registered.
481 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 106 are open to participants now.
Browse Muscular Dystrophy, Duchenne studies →35 of the 233 studies in Muscular Dystrophy, Duchenne with a site in United States are open now. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18+ · Men only
Sarepta Therapeutics, Inc. · Sites in United States
Ages 4+ · Men only
University of Florida · Sites in United States
Ages 6+ · Men only
Vanderbilt University Medical Center · Sites in United States
Ages 8–18 · Men only
University of Rochester · Sites in United States
Ages 0 days–3 yrs · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 65 Muscular Dystrophy, Duchenne studies recruiting now, 30 (46%) set no upper age limit and 33 (51%) stop at 75 or younger; 58 take children under 18; 11 take healthy volunteers.
This study: 7 Years to 14 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
233 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 57 · Phase 2 91 · Phase 3 40 · Phase 4 5
First in 2000; this study’s year is marked. 13 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 331 is above the median of 26 across 332 interventional studies indexed under Muscular Dystrophy, Duchenne.
Median enrollment 25 across the 172 interventional studies, 75 across the 55 observational. Of the 160 that completed or were terminated, 78 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
131 of 233 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,109 studies on the registry; 153 are open to participants now.
Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
Eli Lilly and Company has 1 study filed under Muscular Dystrophy, Duchenne — fewer than ten, so there is no comparison to draw.
20 of the studies in Muscular Dystrophy, Duchenne with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05881408Phase 3Sarepta Therapeutics, Inc.A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) | 2027-05-31 |
| NCT06290713University of FloridaVasodilator and Exercise Study for DMD (VASO-REx) | 2026-11 |
| NCT06450639Hoffmann-La RocheA Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD) | 2026-11-18 |
| NCT03368742Solid Biosciences Inc.Microdystrophin Gene Transfer Study in Adolescents and Children With DMD | 2026-11-30 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
Add all 20 to your calendar (.ics) → With an account.
Among the 233 studies in Muscular Dystrophy, Duchenne with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to determine if tadalafil can slow the decline in walking ability of boys who have Duchenne muscular dystrophy (DMD). The study will also assess the safety of tadalafil and any side effects that might be associated with it in boys who have DMD. Participants will receive study treatment (tadalafil or placebo) for the first 48 weeks of the study, and can then continue into an open label extension (OLE) that consists of two periods during which all participants will receive tadalafil. In OLE period 1, all participants will receive tadalafil for 48 weeks. Participants completing OLE period 1 will continue into OLE period 2 and will receive tadalafil for at least another 48 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo taken orally once daily.
Drug: Placebo
0.3 milligram per kilogram (mg/kg) tadalafil taken orally once daily.
Drug: Tadalafil
0.6 mg/kg tadalafil taken orally once daily.
Drug: Tadalafil
Administered orally
Also known as: LY450190, Cialis
Also known as: Administered orally
Change From Baseline in Six Minute Walk Distance (6MWD) in Meters
6MWD measured the distance in meters a participant was able to walk in 6 minutes. The study used 6MWD procedure modified specifically for use in boys with Duchenne muscular dystrophy (DMD), including standardized verbal encouragement at specific intervals to maintain attention to the test, and use of a "safety chaser" to walk behind the participant during testing (McDonald et al., 2010a). The LS mean (LSM) change from baseline, standard error was derived using mixed model repeated measures (MMRM) methodology with factors for pooled country, treatment, visit, treatment-by-visit interaction and baseline 6MWD as a covariate.
Time frame: Baseline, Week 48
Change From Baseline in the North Star Ambulatory Assessment (NSAA) Global Score
The NSAA is a functional scale specifically designed for ambulant boys with DMD that can provide additional information on motor functions important in maintaining normal ambulation and other activities important to everyday life. The NSAA is a 17-item evaluation of standing, ability to transition from lying to sitting, sitting to standing, and other mobility assessments. Each of the 17 items is evaluated on an ordinal scale of 0, 1, or 2, with higher scores reflecting better performance on the assessment, for a total maximum score of 34. This score was transformed to a 0 to 100 scale for the key analysis (referred to as linearized), with higher transformed scores reflecting better performance.The LS mean (LSM) change from baseline standard error was derived using mixed model repeated measures methodology (MMRM) with factors for pooled country, treatment, visit, treatment-by-visit interaction and Day 1 value as baseline covariate.
Time frame: Baseline, Week 48
Change From Baseline in Timed Function Tests in Seconds
Timed function tests included time it took to rise from floor, walk 10 meters, ascend 4 stairs, and descend 4 stairs.The lower the time in seconds taken, the better the performance. The LS mean change from baseline, standard error, was derived using mixed model repeated measures methodology (MMRM) with factors for pooled country, treatment, visit, treatment-by-visit interaction and Day 1 value as baseline covariate.
Time frame: Baseline, Week 48
Time to Persistent 10% Worsening in 6MWD
Time on study until the 6MWD becomes 10% less than the baseline 6MWD and continues at that level or lower until the end of study.
Time frame: Baseline through Week 48
Time to Persistent 10% Worsening in Timed Function Tests (TFT)
Time on study until the TFT becomes 10% worse than the baseline TFT and continues at that level or lower until the end of study. The time to persistent 10% worsening is the observed time after baseline until the first observed timepoint where their time used for the TFTs is \>110% of the baseline time and all the time values observed afterward are also \>110% of baseline. If the participant discontinues prior to experiencing persistent worsening, this outcome for the participant is censored at the date of discontinuation of the double-blind period. Only participants with complete evaluable data were analyzed. Complete evaluable data was defined as having baseline measurement, complete dates at evaluable visits and a post-baseline measurement at each evaluable visit.
Time frame: Baseline through Week 48
Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Scores
PODCI includes a Global Functioning Scale and 5 core scales:Upper Extremity and Physical Function,Transfer/Basic Mobility, Sports/Physical Functioning, Pain/Comfort,and Happiness.The Global Functioning Scale is the mean of the mean scores from 4 of the 5 core scales (all except the happiness core scale).The following PODCI scores were prespecified in the protocol for analysis: Global Functioning, Upper Extremity and Physical Function,Transfer/Basic Mobility, and Sports/Physical Functioning. The Global Functioning Scale and each of the core scales were standardized so that a score of "0" represents a poor outcome/worse health, while "100" is the best possible outcome/best health (i.e., complete range of each score is 0 to 100, with higher scores representing better functioning). The LS mean (LSM) change from baseline,standard error was derived using MMRM with factors for pooled country, treatment, visit, treatment-by-visit interaction and baseline PODC scale as covariate.
Time frame: Baseline, Week 48
Pharmacokinetics (PK): Apparent Clearance (CL/F) of Tadalafil
The data reported are population estimate and inter-patient variability.
Time frame: Weeks 4, 12, 24 and 36: -1 Hour up to 24 Hours Postdose
| Milestone | Placebo | 0.3 mg/kg Tadalafil | 0.6 mg/kg Tadalafil |
|---|---|---|---|
| Started | 116 | 102 | 113 |
| Received at least one dose of study drug | 116 | 102 | 112 |
| Completed | 111 | 98 | 107 |
| Not completed | 5 | 4 | 6 |
| Withdrew: Adverse event | 2 | 2 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 1 |
| Withdrew: Withdrawal by parent/guardian | 2 | 2 | 4 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 |
| Milestone | Placebo | 0.3 mg/kg Tadalafil | 0.6 mg/kg Tadalafil |
|---|---|---|---|
| Started | 0 | 150 | 165 |
| Completed | 0 | 139 | 158 |
| Not completed | 0 | 11 | 7 |
| Withdrew: Adverse event | 0 | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
| Withdrew: Withdrawal by parent/guardian | 0 | 8 | 2 |
| Withdrew: Withdrawal by subject | 0 | 2 | 2 |
6MWD measured the distance in meters a participant was able to walk in 6 minutes. The study used 6MWD procedure modified specifically for use in boys with Duchenne muscular dystrophy (DMD), including standardized verbal encouragement at specific intervals to maintain attention to the test, and use of a "safety chaser" to walk behind the participant during testing (McDonald et al., 2010a). The LS mean (LSM) change from baseline, standard error was derived using mixed model repeated measures (MMRM) methodology with factors for pooled country, treatment, visit, treatment-by-visit interaction and baseline 6MWD as a covariate.
| Meters | Placebo | 0.3 mg/kg Tadalafil | 0.6 mg/kg Tadalafil |
|---|---|---|---|
| Change From Baseline in Six Minute Walk Distance (6MWD) in Meters | -50.99 ± 9.316 | -64.71 ± 9.809 | -59.08 ± 9.397 |
The NSAA is a functional scale specifically designed for ambulant boys with DMD that can provide additional information on motor functions important in maintaining normal ambulation and other activities important to everyday life. The NSAA is a 17-item evaluation of standing, ability to transition from lying to sitting, sitting to standing, and other mobility assessments. Each of the 17 items is evaluated on an ordinal scale of 0, 1, or 2, with higher scores reflecting better performance on the assessment, for a total maximum score of 34. This score was transformed to a 0 to 100 scale for the key analysis (referred to as linearized), with higher transformed scores reflecting better performance.The LS mean (LSM) change from baseline standard error was derived using mixed model repeated measures methodology (MMRM) with factors for pooled country, treatment, visit, treatment-by-visit interaction and Day 1 value as baseline covariate.
| Units on a scale | Placebo | 0.3 mg/kg Tadalafil | 0.6 mg/kg Tadalafil |
|---|---|---|---|
| Change From Baseline in the North Star Ambulatory Assessment (NSAA) Global Score | -8.80 ± 1.104 | -9.31 ± 1.181 | -8.96 ± 1.115 |
Timed function tests included time it took to rise from floor, walk 10 meters, ascend 4 stairs, and descend 4 stairs.The lower the time in seconds taken, the better the performance. The LS mean change from baseline, standard error, was derived using mixed model repeated measures methodology (MMRM) with factors for pooled country, treatment, visit, treatment-by-visit interaction and Day 1 value as baseline covariate.
| Seconds | Placebo | 0.3 mg/kg Tadalafil | 0.6 mg/kg Tadalafil |
|---|---|---|---|
| Rise from the Floor(n=92,75,89) | 4.16 ± 1.120 | 3.60 ± 1.223 | 4.81 ± 1.156 |
| 10 Meter Walk/Run(n=105,90,100) | 1.11 ± 0.204 | 0.95 ± 0.226 | 1.12 ± 0.217 |
| Stair Climb (n=116,96,110) | 3.96 ± 1.041 | 4.10 ± 1.154 | 5.82 ± 1.072 |
| Stair Descend(n=115,95,110) | 3.19 ± 0.827 | 2.07 ± 0.915 | 3.27 ± 0.853 |
Time on study until the 6MWD becomes 10% less than the baseline 6MWD and continues at that level or lower until the end of study.
| Days | Placebo | 0.3 mg/kg Tadalafil | 0.6 mg/kg Tadalafil |
|---|---|---|---|
| Time to Persistent 10% Worsening in 6MWD | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Time on study until the TFT becomes 10% worse than the baseline TFT and continues at that level or lower until the end of study. The time to persistent 10% worsening is the observed time after baseline until the first observed timepoint where their time used for the TFTs is \>110% of the baseline time and all the time values observed afterward are also \>110% of baseline. If the participant discontinues prior to experiencing persistent worsening, this outcome for the participant is censored at the date of discontinuation of the double-blind period. Only participants with complete evaluable data were analyzed. Complete evaluable data was defined as having baseline measurement, complete dates at evaluable visits and a post-baseline measurement at each evaluable visit.
| Days | Placebo | 0.3 mg/kg Tadalafil | 0.6 mg/kg Tadalafil |
|---|---|---|---|
| Rise from the Floor (n=81,67,77) | 253.0 (170.0 to NA) | NA (NA to NA) | NA (NA to NA) |
| Stair Climb (n=112,91,107) | 255.0 (252.0 to NA) | 259.0 (176.0 to NA) | 253.0 (185.0 to NA) |
| 10 Meter Walk/Run (n=98,83,91) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
| Stair Descend (n=110,91,108) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
PODCI includes a Global Functioning Scale and 5 core scales:Upper Extremity and Physical Function,Transfer/Basic Mobility, Sports/Physical Functioning, Pain/Comfort,and Happiness.The Global Functioning Scale is the mean of the mean scores from 4 of the 5 core scales (all except the happiness core scale).The following PODCI scores were prespecified in the protocol for analysis: Global Functioning, Upper Extremity and Physical Function,Transfer/Basic Mobility, and Sports/Physical Functioning. The Global Functioning Scale and each of the core scales were standardized so that a score of "0" represents a poor outcome/worse health, while "100" is the best possible outcome/best health (i.e., complete range of each score is 0 to 100, with higher scores representing better functioning). The LS mean (LSM) change from baseline,standard error was derived using MMRM with factors for pooled country, treatment, visit, treatment-by-visit interaction and baseline PODC scale as covariate.
| Units on a scale | Placebo | 0.3 mg/kg Tadalafil | 0.6 mg/kg Tadalafil |
|---|---|---|---|
| Global Functioning Scale (n=41,34,34) | -8.81 ± 1.770 | -7.36 ± 1.929 | -7.34 ± 1.888 |
| Upper Extremity & Physical Function | -5.47 ± 1.901 | -3.73 ± 2.060 | -2.47 ± 2.042 |
| Transfer/Basic Mobility Core Scale | -14.26 ± 3.037 | -12.50 ± 3.260 | -12.78 ± 3.279 |
| Sports/Physical Functioning Core Scale | -12.47 ± 2.362 | -11.98 ± 2.552 | -7.88 ± 2.537 |
The data reported are population estimate and inter-patient variability.
| Liter per hour (L/hr) | 0.3 mg/kg Tadalafil and 0.6 mg/kg Tadalafil |
|---|---|
| Pharmacokinetics (PK): Apparent Clearance (CL/F) of Tadalafil | 1.79 ± 29.6 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo - DB | — | 5/116 (4.3%) | 83/116 (71.6%) |
| 0.3 mg/kg Tadalafil -DB | — | 4/102 (3.9%) | 82/102 (80.4%) |
| 0.6 mg/kg Tadalafil - DB | — | 6/112 (5.4%) | 92/112 (82.1%) |
| 0.3 mg/kg Tadalafil - OLE | — | 6/150 (4%) | 68/150 (45.3%) |
| 0.6 mg/kg Tadalafil - OLE | — | 9/165 (5.5%) | 84/165 (50.9%) |
| Event | Placebo - DB | 0.3 mg/kg Tadalafil -DB | 0.6 mg/kg Tadalafil - DB | 0.3 mg/kg Tadalafil - OLE | 0.6 mg/kg Tadalafil - OLE |
|---|---|---|---|---|---|
| FallInjury, poisoning and procedural complications | 1/116 | 0/102 | 2/112 | 1/150 | 1/165 |
| Femur fractureInjury, poisoning and procedural complications | 0/116 | 0/102 | 2/112 | 1/150 | 1/165 |
| MyocarditisCardiac disorders | 0/116 | 1/102 | 0/112 | 0/150 | 0/165 |
| Gastrointestinal infectionInfections and infestations | 0/116 | 1/102 | 0/112 | 0/150 | 0/165 |
| PneumoniaInfections and infestations | 0/116 | 1/102 | 0/112 | 0/150 | 1/165 |
| Muscle contractureMusculoskeletal and connective tissue disorders | 0/116 | 1/102 | 0/112 | 0/150 | 0/165 |
| PharyngotonsillitisInfections and infestations | 0/116 | 0/102 | 1/112 | 0/150 | 0/165 |
| Pneumonia adenoviralInfections and infestations | 0/116 | 0/102 | 1/112 | 0/150 | 0/165 |
| VaricellaInfections and infestations | 0/116 | 0/102 | 1/112 | 0/150 | 0/165 |
| Tendinous contractureMusculoskeletal and connective tissue disorders | 1/116 | 0/102 | 1/112 | 1/150 | 0/165 |
| Event | Placebo - DB | 0.3 mg/kg Tadalafil -DB | 0.6 mg/kg Tadalafil - DB | 0.3 mg/kg Tadalafil - OLE | 0.6 mg/kg Tadalafil - OLE |
|---|---|---|---|---|---|
| HeadacheNervous system disorders | 36/116 | 40/102 | 43/112 | 8/150 | 14/165 |
| FallInjury, poisoning and procedural complications | 24/116 | 18/102 | 22/112 | 16/150 | 15/165 |
| NasopharyngitisInfections and infestations | 16/116 | 8/102 | 18/112 | 8/150 | 12/165 |
| VomitingGastrointestinal disorders | 14/116 | 6/102 | 17/112 | 9/150 | 10/165 |
| Erection increasedReproductive system and breast disorders | 3/116 | 10/102 | 17/112 | 2/150 | 4/165 |
| AbasiaGeneral disorders | 6/116 | 14/102 | 9/112 | 12/150 | 16/165 |
| Spontaneous penile erectionReproductive system and breast disorders | 4/116 | 13/102 | 13/112 | 3/150 | 4/165 |
| PyrexiaGeneral disorders | 4/116 | 11/102 | 9/112 | 7/150 | 6/165 |
| Back painMusculoskeletal and connective tissue disorders | 9/116 | 11/102 | 7/112 | 7/150 | 9/165 |
| Upper respiratory tract infectionInfections and infestations | 10/116 | 10/102 | 12/112 | 6/150 | 8/165 |
All participants who were randomized to study drug.
| Age, Continuous(years) | Placebo | 0.3 mg/kg Tadalafil | 0.6 mg/kg Tadalafil | Total |
|---|---|---|---|---|
| Mean | 9.4 ± 1.76 | 9.9 ± 2.26 | 9.5 ± 1.71 | 9.6 ± 1.92 |
| Sex: Female, Male(Participants) | Placebo | 0.3 mg/kg Tadalafil | 0.6 mg/kg Tadalafil | Total |
|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 |
| Male | 116 | 102 | 113 | 331 |
| Race (NIH/OMB)(Participants) | Placebo | 0.3 mg/kg Tadalafil | 0.6 mg/kg Tadalafil | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 2 | 2 |
| Asian | 15 | 16 | 20 | 51 |
| Native Hawaiian or Other Pacific Islander | 3 | 1 | 3 | 7 |
| Black or African American | 0 | 0 | 1 | 1 |
| White | 96 | 82 | 84 | 262 |
| More than one race | 2 | 3 | 2 | 7 |
| Unknown or Not Reported | 0 | 0 | 1 | 1 |
| Region of Enrollment(Participants) | Placebo | 0.3 mg/kg Tadalafil | 0.6 mg/kg Tadalafil | Total |
|---|---|---|---|---|
| Argentina | 7 | 4 | 6 | 17 |
| Russian Federation | 4 | 4 | 4 | 12 |
| United States | 39 | 34 | 34 | 107 |
| Japan | 6 | 5 | 6 | 17 |
| Spain | 9 | 7 | 12 | 28 |
| Canada | 8 | 7 | 8 | 23 |
| Netherlands | 2 | 1 | 3 | 6 |
| Turkey | 5 | 7 | 8 | 20 |
| Belgium | 8 | 5 | 4 | 17 |
| Taiwan | 6 | 4 | 8 | 18 |
| Korea, Republic of | 3 | 4 | 5 | 12 |
| Italy | 8 | 8 | 8 | 24 |
| France | 3 | 2 | 2 | 7 |
| Germany | 8 | 10 | 5 | 23 |
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
The record gives a start of Sep 2013, a primary completion of Dec 2015 and a completion of Mar 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2017, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tadalafil
Muscular Dystrophy, Duchenne →